Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume – Here’s Why

Pharming Group (NASDAQ:PHAR) shares saw strong trading volume on Friday . 9,009 shares changed hands during mid-day trading, an increase of 51% from the previous session’s volume of 5,954 shares.The stock last traded at $8.40 and had previously closed at $8.86.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research report on Tuesday, December 17th. Jefferies Financial Group assumed coverage on Pharming Group in a research report on Monday, December 9th. They issued a “buy” rating and a $14.00 price target on the stock.

Pharming Group Stock Down 3.8 %

The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The company has a market cap of $547.65 million, a price-to-earnings ratio of -30.96 and a beta of -0.10. The business has a 50-day simple moving average of $9.17 and a 200-day simple moving average of $8.57.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its position in shares of Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.